Business Services Industry

GenVec to Present at BioCentury and Thomson Financial's Future Leaders in the Biotech Industry Conference

Business Wire, March 22, 2007

GAITHERSBURG, M.D. -- GenVec, Inc. (Nasdaq:GNVC) today announced that Paul H. Fischer, Ph.D., President and CEO, will present a corporate overview and highlight recent developments at the 2007 Future Leaders in the Biotech Industry Conference hosted by BioCentury and Thomson Financial. Dr. Fischer's presentation will take place on Thursday, March 29, 2007 at 4:00 p.m. ET, at the Millennium Broadway Hotel in New York City.

A live webcast of Dr. Fischer's presentation will be available on the Company's web site at www.genvec.com and archived for 30 days. To access the webcast or the replay, go to the "Investor Relations" page, and click on the link to the Webcasts and Data section.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade[TM] is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu, and foot-and-mouth disease. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale